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ABSTRACT
DEVELOPMENT OF A
THIN-FILM POROUS-MICROELECTRODE ARRAY (P-MEA) FOR
ELECTRICAL STIMULATION OF ENGINEERED CARDIAC TISSUE
Hiren Vrajlal Trada
December 1st, 2014
Electrical stimulation has been increasingly used by research groups to enhance
and increase maturation of cells in an engineered cardiac tissue (ECT). Current methods
are based on using off-the-shelf wires or electrodes to deliver a stimulus voltage to the
in-vitro tissue in culture medium. A major issue with this approach is the generation of
byproducts in the medium due to the voltage levels required, which are typically in the
range of 5V-10V. No solution currently exists that can accomplish electrical stimulation
of cells in an ECT at a low voltage level. Therefore, in this study a novel, porous, thinfilm, microelectrode array (PMEA) device is proposed. The primary advantage of this
device is the ability to successfully function at a very low voltage thus minimizing any
undesirable oxidative byproducts in the culture environment or cell injury. This was
achieved by designing and fabricating a thin device capable of being embedded in the
ECT to deliver voltage. The P-MEA device is essentially a thin-film cable i.e. a
conducting wire encapsulated with an insulating material; in this case thin-film gold
electrodes sandwiched between two layers of insulating polyimide.
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Major features of the P-MEA include overall dimensions of 10mm width and
82mm length, four arms to allow movement of the individual sensor pads within ECTs,
each embedded electrode arm incorporates eight 100μm x 200μm rectangular pores
surrounding a 950μm x 340μm exposed electrode, large pads on either side of the porous
embedded sensor to function as return electrodes, suture holes to aid in-vivo suturing and
stabilization and eight electrode connector pads.
Average thickness of the device was 16µm, with an average electrode film
thickness of 0.4μm. Electrode resistance ranged from 69.45Ω to 78.52Ω. Electrochemical
impedance spectroscopy was performed on the P-MEA electrodes and it confirmed that
the P-MEA successfully operates in the 0.01V to 1.0V range with favorable charge
transfer characteristics. Proof of principle experiments confirmed the ability of the PMEA to effectively embed within the ECT and electrically stimulate it during chronic,
in-vitro culture. Histology imaging shows that the embedding of the device has no
adverse effects on the ECT and the cardiomyocytes are aligned within the tissue.
Experiments are ongoing to evaluate the role of electrical stimulation on the maturation
and function of ECTs which are made of stem cells and other sources.
In summary, this device is capable of safe low-voltage electrical stimulation of
engineered cardiac tissues (ECTs); it has been designed, fabricated, and its ability to
function as a low-voltage stimulus device has been validated using electrochemical tests
and in-vitro culture experiments. The design and fabrication of the device went through
three major iterations. A final manufacturing process was refined and successfully
transferred to the UofL MNTC staff for subsequent manufacturing.
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CHAPTER 1
INTRODUCTION

1.1 Cardiac Injury, Remodeling, and Repair
Cardiovascular Disease (CVD) is the leading cause of mortality in the United
States (and indeed worldwide). The American Heart Association (AHA), working in
conjunction with other government health agencies, releases an annual report titled
‘Heart Disease and Stroke Statistics’, detailing the statistics relating to heart disease in
the United States [1]. In their ‘2014 Update’ the AHA reveals that Cardiovascular
Diseases account for more than 30% of all deaths in the United States.
While this number is large, the rate has been steadily declining over the last
decade. However, even with the declining rate, the burden of CVD remains very high
with total annual costs in excess of $650 billion. Projected estimates have this number
crossing an unsustainable $1 trillion in the next 20 years (see chart shown in Figure 1.1).
The AHA lays out target goals to reduce this burden by emphasizing healthy lifestyles
and habits. Heart disease can be prevented to a certain extent by a healthy lifestyle, but
not completely eliminated.
One fundamental cause for the large financial and health burdens of heart disease
is the inability of the heart to replace damaged heart cells following injury. The heart
tissue is made up of multiple cells types including cardiomyocytes (CM), fibroblasts, and
endothelial cells within a complex extra-cellular matrix [2, 3]. The human heart consists
1
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has negative impacts on cardiac muscle performance by increasing tissue stiffness,
altering contractile properties, and introducing barriers to efficient tissue electrical
depolarization and mechanical shortening.
It seems logical that the damage caused due to a loss of CM could be reversed by
an influx of new cells. For this to occur, the cardiac tissue needs to be supplied with new
functional, healthy CM to repair the damaged area. This can be accomplished in two
ways; stimulation of in situ CM proliferation or implantation of new CM via various
methods. To date, no effective methods to trigger the proliferation of in situ mature CM
has been validated, as thus, this approach is not a current pre-clinical or clinical option.
However, there have been various approaches to implant a wide range of cells and cell
formulations into preclinical models of cardiac injury and into patients with cardiac
injury. One strategy to stimulate cardiac repair is the direct injection of cells into
damaged regions of the heart with the goal of regenerating healthy myocardium.
However, this method of direct injection is not reliable since the implanted cells
uniformly die within 30 days [4]. There are various theories as to the etiology of cell
death for these implanted cells including a hostile microenvironment (hypoxia,
inflammation), abnormal cell-cell interactions, and abnormal cell-matrix interactions.
An alternate approach is the generation of 3-dimensional engineered cardiac
tissues (ECTs) that can be implanted onto the heart in order to restore cardiac tissue and
function. The focus of this thesis is the development of a strategy and device for the
electrical stimulation of engineered cardiac tissues, and so the majority of the following
text focuses on that application of cellular repair of the damaged heart.
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The field of Tissue Engineering, more specifically, Cardiac Tissue Engineering,
uses scaffolds to create tissue made of cardiac cells. Engineered Cardiac Tissue (ECT)
made from such cells can be used as in-vitro models for research studies on myocardial
function, pharmacology, and diseases. The overarching goal of Cardiac Tissue
Engineering is to develop cardiac tissues in-vitro with the same morphological and
functional properties as native in vivo myocardium. The engineered tissues can be
implanted onto a diseased or an infarcted heart wall, which can no longer perform its
cardiac functions, with the purpose of repairing the area and to introduce some sort of
functionality back to the damaged area.
To be feasible for implantation, an in-vitro engineered cardiac tissue needs to
have similar properties to its native in vivo target tissue. During embryo development the
growing heart consists of cells that differentiate and proliferate into cardiac tissues. These
cardiomyocytes are subject to mechanical loading and electrical stimulus to drive their
development; as the cells mature, the heart forms. Soon after birth, the cells lose the
ability to proliferate and we are born with all the cardiac cells that we will ever have in a
lifetime.
Cardiac tissue can be engineered from a variety of cell sources; however mature
cells do not have the ability to proliferate and are therefore less desirable to form and
remodel ECTs. Immature cells from embryonic sources have the ability to differentiate
and proliferate if they are subjected to the mechanical and electrical conditions found in
native tissue. A 2-dimensional structure cannot mimic a native biological environment;
hence the need arises to create a bio-mimetic 3-dimensional structure to simulate native
tissue. Despite 3D geometries, the maturation of in-vitro ECTs can be delayed relative to
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native in vivo immature myocardium, leading to the use of various conditioning protocols
to accelerate ECT maturation [5]. In-vitro cyclic mechanical loading has been shown to
accelerate ECT CM proliferation and functional maturation similar to the biologic effects
of mechanical load in vivo [6]. Electrical stimulation has also been used to accelerate the
maturation of proliferating stem cell derived CM within ECTs using adjacent electrodes
to connect with the engineered tissue [7-9]. These electrode arrays can be used to
quantify cardiac tissue maturation via the voltage thresholds required to simulate CM
contraction and record depolarization and conduction.
Most research groups accomplish in-vitro stimulation of excitable tissue, such as
ECTs, using readily available, off-the-shelf components to achieve in-vitro electrical field
stimulation. These are primarily wires made from platinum, stainless steel electrodes or
carbon rods as shown in the layout in figure 1.2 [7, 9-12].

Typical ECT

Rods/Wires
Figure 1.2: Typical setup used by most research groups to achieve electrical stimulation. More
often than not it involves two conducting rods (platinum or carbon) to carry the electrical signal
from a stimulator.
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A simple rod electrode may not be ideally suited to the task due to the high
voltage required to initiate tissue depolarization and pacing (usually 5V to 10V).
However, these voltages far exceed the water electrolysis threshold voltage of 1.23V [13]
and can produce gas bubbles in the culture medium which may impede nutrient stability,
delivery, and cause cell injury. Another confounding variable is the high-glucose content
of standard ECT culture media. Electrical voltages in the range of 4V to 5V (and above)
cause redox reactions in the media, reducing and oxidizing glucose to form sorbitol and
gluconate respectively [14, 15]. The negative consequences of released gases, compounds
and substrate oxidation can also lead to undesirable shifts in culture media pH. A solution
which has been designed solely for the purpose of investigating cardiac tissue does not
exist.
In this dissertation, a novel device is presented that was designed and fabricated to
accomplish the tasks of stable, in-vitro, acute and chronic ECT electrical stimulation at
much lower threshold voltages via direct contact and coupling to cells embedded within
ECT. This was achieved by designing and fabricating a thin-film, porous, multiple
electrode array (P-MEA) that could be embedded within the ECT at the time of ECT
formation.
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1.2 Objective Statement
The objective of this study is to develop a thin-film microelectrode array that can be
embedded into an engineered cardiac tissue for the purpose of electrical stimulation.

1.3 Hypothesis
A microfabricated thin-film device embedded into an engineered cardiac tissue can
achieve efficient electrical stimulation of cells at a much lower voltage compared to
existing methods.

Corollary 1:
Embedding a thin-film device will not cause adverse effects or reactions in the
tissue.
Corollary 2:
Electrical stimulation of ECT with the aid of this device can be achieved at 1V or
less (compared to 5V or more for existing methods).
Corollary 3:
Electrical stimulation of ECT (using said device) can aid in the functional
maturation of the ECT.
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1.4 Specific Aims
Specific Aim 1:
To design and develop a P-MEA device via an iterative design process for use in
ECT experiments. This includes designing and fabricating a custom macro-micro
interface for electrical coupling to pacing and/or recording systems.
Specific Aim 2:
To develop the fabrication process flow, and in subsequent iterations, to refine the
process to obtain high yield suitable for repetitive manufacturing.
Specific Aim 3:
To perform electrochemical characterization of the device to determine safe
operating limits. This includes data analysis and computer simulation of the device using
an equivalent electrochemical model.
Specific Aim 4:
To accomplish in-vitro electrical stimulation of Engineered Cardiac Tissue (ECT),
including comparison of three groups of ECTs: [1] Control (non-embedded ECTs),
[2] Sham ECTs (embedded but non-stimulated), and [3] Device ECTs (embedded and
stimulated).
(a) Acute Pacing - data generation and collection of threshold voltages, intrinsic
beat rates and maximum pacing rates.
(b) Chronic Pacing – effects of electrical stimulation on threshold voltages, beat
rates, and on tissue morphology, proliferation, and maturation.
Specific Aim 5:
Validate the findings through peer-reviewed publications.
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1.5 Backgrou
und
The heart
h
is the first
f
major organ
o
of thee human boddy to develoop and form
m in a
bryo. It is th
he engine which
w
drivess the circulaatory system
m of the boddy to
grrowing emb
distribute blo
ood and nutrrients to the tissues and organs. Thee heart is maade up of caardiac
ceells known as
a cardiomyo
ocytes (CM)) which typiically contraact (in unisonn) about 3 bbillion
tiimes in an av
verage humaan lifespan [3,
[ 4]. This m
mechanical aability of thee cardiomyoocytes
to
o contract in
n unison alllows the heeart to functtion as a m
mechanical ppump to gennerate
prressure and deliver blo
ood. The mechanical
m
ccontraction iis caused bby the changge in
ellectrical potential of thee cell membranes due too the flow oof ions acrosss the membbrane.
Electrically
E
sp
peaking, 99%
% of the CM
Ms are used ffor mechaniccal contractiion and 1% oof the
ceells behave as the pacemaker off the heart to initiate an action potential. T
These
‘p
pacemaker’ cells can bee found in (1)
( the sinoaatrial (SA) nnode, (2) thee atrioventriicular
(A
AV) node (3
3) the bundlee of His (atriioventricularr bundle), annd (4) Purkinnje fibers (F
Figure
1.3). The SA
A node is thee place where the actionn potentials are initiatedd and thus iis the
prrimary pacemaker of th
he heart. Thee ventricularr and atrial ccells perform
m the mechaanical
pu
umping baseed on the eleectrical signaals from the SA node.

Figure 1.3: Ellectrical con
nduction systtem of the heeart. [3].
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Blood flows through the heart without stopping; the atrium receives it and pushes
it to the ventricles which send it out of the heart. If the blood flow decreases or stops for
any reason, the heart suffers a myocardial infarction (MI). Cells start dying in the affected
area and a healing response is initiated. However, adult cardiac cells cannot divide and
proliferate to replace the ones that are lost. Scar tissue forms over the affected area which
results in diminished capacity of the heart.
Strategies for repair of a diseased heart have had two approaches; (a) direct
injection of cells into the diseased site, (b) grafting a cardiac patch on to the affected area
[5, 32]. The issue with direct injection of cells into the damaged tissue is that nearly 90%
of the cells die out within 2-4 weeks of application [5]. The second approach is the focus
of cardiac tissue engineering. Interest in tissue engineering by numerous research groups
in the past decade or so has generated a wealth of knowledge about the field [6, 7, 12, 13,
15, 21, 37, 39, 41-48].
To repair the damage caused due to a MI, a cardiac patch has been suggested,
which can be grafted on to the scar tissue to render back a degree of functionality. A
cardiac patch is essentially a scaffold made of collagen or similar natural polymer with
cardiac cells seeded on to the scaffold. The cells for such patches can be obtained from a
variety of sources such as; embryonic or neonatal cardiomyocytes, embryonic stem cells
(ESC) and induced pluripotent stem cells (IPS) among others. A novel method was
presented by Hirose et. al. where they used human aortic endothelial cells (HAECs) to
create a sheet of a monolayer of cells, called cell sheets [16]. These cell sheets are seeded
on temperature sensitive tissue culture dish surfaces which change to hydrophilic when
their temperature is lowered to 32°C from the normal culture temperature of 37°C. This
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causes the sheets to detach from the culture dish without the use of digestive enzymes.
Shimuzu et al were successful in creating multiple layers of electrically coupled cell
sheets and grafting on rat hearts [17-20].
The goal of cardiac tissue engineering is to generate functional 3D tissues that can
be implanted in-vivo to facilitate cardiac repair and regeneration. An engineered tissue
comprises cellular and extracellular components, undergoes remodeling and maturation
during in vitro culture, and requires both structural and functional integration for
successful in vivo implantation and survival [37]. In general, successful integration of
engineered tissues requires that the implanted biomaterials have both biologic and
biomechanical compatibility with the target tissues and microenvironment [38]. These
general principles are relevant to the generation of 3D engineered cardiac tissues (ECTs)
and various approaches have been used to generate in vitro functional cardiac tissues
from a variety of stem, embryonic, fetal, and neonatal cell types [39-44], various
biomaterial formulations [45-48], with successful in vivo implantation [49-51].
Cardiac cells in their natural biological environment are subjected to
dynamically changing mechanical and electrical forces during development and in
response to injury [52]. Standard 2D cell cultures do not mimic this dynamic
environment, hence 3D environments are required for immature cardiomyocytes (CM) to
proliferate, differentiate, and form functional tissues.

These 3D formulations are

designed to provide realistic mechanical loading conditions with adequate nutrient
support to facilitate tissue maturation.
Despite 3D geometries, the maturation of in vitro ECTs can be delayed
relative to native in vivo immature myocardium, leading to the use of various
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co
onditioning protocols to
o accelerate ECT
E
maturaation [10]. Cyyclic mechaanical loadinng has
been shown to accelerate ECT CM prroliferation aand functionnal maturatioon [54]. Elecctrical
sttimulation has
h also beeen used to accelerate
a
thhe maturatioon of prolife
ferating stem
m cell
derived CM within
w
ECTss using adjaccent electroddes to conneect with the eengineered ttissue
[1
11, 28, 29, 55].
Most research gro
oups, focusin
ng on in-vittro stimulation of ECT, use off-the--shelf
co
omponents to achieve in-vitro field electricall stimulationn such as ccarbon rodss and
platinum wirees. The volttages associaated with suuch a setup iis usually inn the range oof 5V
an
nd above. Radisic
R
et al used two 1//4-inch-diam
meter carbonn rods placedd 1 cm aparrt and
co
onnected to a stimulator with platin
num wires [[10, 22]. Tanndon and Cannizzaro uused a
siimilar setup for their exp
periments with scaffoldss suspended between carrbon rods (F
Figure
1.4) [24-27].

up used by
y most grouups for elecctrical stim
mulation of ECT.
Figure 1.4: Typical setu
Scaffolds seeeded with ceells are suspended betweeen carbon or steel rodds connectedd with
platinum wirees [24-27].
The isssue with usiing an off-th
he-shelf rod or electrodee is the high value of volltages
reequired to sttimulate the tissues with
h reported vvalues ranginng from 5V--10V [10, 222, 24,
27]. These vo
oltages far exceed the water
w
electrollysis threshoold voltage oof 1.23V andd can
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produce gas bubbles in the culture medium which may impede nutrient stability and
delivery [30]. Another variable is the high-glucose content of standard ECT culture
media. Electrical voltages in the range of 5V cause redox reactions in the media, reducing
and oxidizing glucose to form sorbitol and gluconate respectively [31-34]. The negative
consequences of released gases, compounds and substrate oxidation can also lead to
undesirable shifts in culture media pH. Moreover, electrical stimulation at high voltages
can cause direct damage to the tissue by local heating and/or over-stimulation [35]. To
eliminate these problems the stimulation voltage should be kept as low as possible,
ideally less than the water electrolysis voltage level of 1.23V.
The thin-film porous microelectrode array presented in this dissertation, aims to
eliminate the problems associated with current methods by embedding an electrode inside
the ECT. The device would be encapsulated by the tissue and make direct contact with
the cells during electrical stimulation. This would allow the use of low voltage levels to
accomplish safe in-vitro pacing of ECT. To the best of knowledge, with an investigation
of past and present published work, such a device does not exist for electrical stimulation
of engineered cardiac tissue. A successful P-MEA device would be a unique contribution
to the field of cardiac tissue engineering.

13

CHAPTER II
DESIGN

2.1 Initial Design
The ECT utilized in this research are small, 3-dimensional, cylindrical, gelatinous
structures primarily comprised of collagen, matrigel and cardiac cells; approximately
15mm in length and 2mm in diameter [40]. The ECT was grown inside a commercially
available 6 culture well plate (Tissue Train Plate, FlexCell, International) that includes
two anchor end tabs in each well. The microelectrode array had to interface with the ECT
and provide an external electrical connection. To determine the optimal device
dimensions for embedding the device in the 3D ECT, paper mock-ups were used inside
the culture well (Figure 2.1). This allowed the determination of device features that were
essential to the primary function as well as additional convenience features.
The following key design areas were identified using the mock setup: the
embedded portion, the dimensions of the device, and the contacts for external
connections. The embedded portion was the most critical area of the device since the
cells in the tissue interact with exposed pads in the device. This required a metal
electrode region with maximum contact surface area possible within the tissue area as
well as a relatively strong physical connection. Since the tissue comprises of cardiac cells
it has native beating which results in physical movement of the ECT.
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6
culturre plate used
d for ECT ccreation. Thhe well on tthe top-left hhas a
Figure 2.1: 6-well
mock
m
wooden
n ECT betw
ween the end tabs. The w
well on the toop right has the paper m
mockup
p device. Th
he base of eaach well is covered
c
by a deformablee silicone meembrane.
To aid mechanical retention of the devvice inside tthe ECT annd to prevennt the
device from becoming dislodged
d
during
d
in-vittro culture aand in-vivo implant, itt was
decided to in
ncorporate a ‘porous’ feeature in thee device. Fuurthermore, tto help miniimize
an
ny adverse effect
e
the em
mbedded dev
vice may havve on the maaterial propeerties of the ECT,
th
he embedded
d portion of the device was
w split intoo four separaate arms disttributed alonng the
width
w
of thee device. The
T
decreassed surface area createed with thee porous ddesign
en
nhances/optiimizes cell viability
v
and
d also allowss for free naatural movem
ment by the ECT
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during in-vitro culture. A exposed metal electrode in each embedded arm makes contact
with the cells. The porosity of the structure increases retention of the device in the tissue.
The device has to feed over the top edge of the covered culture plate to an external
connector, requiring a relatively long conductive connector element. Using the initial
mock-up, approximate dimensions for the device were determined.
(a) Composite length between 50mm and 90mm.
(b) Width of 20mm.
(c) Total of 4 arms with porous features in each “arm” for embedment.
(d) Porous features should allow 2-4 exposed electrodes in each arm.
A design based on these criteria was created and is featured in Figure 2.2. Total
dimensions of the device are 50mm x 20mm, the four arms are ‘10mm x 2mm’ separated
by a distance of 4mm each. Each individual arm consists of a porous grid of 5 x 25
openings and each opening is 200µm x 200µm in size. Spacing between each porous
opening is also 200µm in each direction. The green rectangle represents an ECT and is
used to depict the approximate positioning of the ECT within the device.
The design was fabricated using standard microfabrication techniques and several
prototypes were created using a single layer of polymer material. The purpose of the
design was to study the physical effects of embedding the device into the ECTs and
material bioeffects on the engineered tissues. To achieve this goal, it was not necessary to
include electrodes in the prototype. Hence, version 1 of the P-MEA device does not
feature any metal electrodes or connection pads. The initial idea was to include space for
four electrodes in each arm for a total of sixteen electrodes in each device.
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Reppresentation of an ECT

Figure 2.2: P-MEA
P
deviice, version 1. A sectionn of the porrous featuree is shown iin the
blow-up. Thee ‘rectangle’ denotes the placement oof the ECT.

The devices
d
weree fabricated and used inn pilot experriments to juudge the phyysical
efffects of the device on ECTs.
E
The prrimary draw
wback of this initial protootype versionn was
th
he width of the
t device; at
a a width off 20mm this vversion of thhe device prooved to be hhighly
disruptive of the tissue sttructure. Mo
oreover, the number of pporous opennings in the mesh
sttructure spreead out the tiissue during
g ECT creatioon and resullted in a veryy thin, spreaad out
an
nd shapelesss 3-dimensiional structu
ures. The rresults of thhe pilot triaals were useed to
determine thee changes neecessary for the
t next verssion of the ddevice.
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2.2 Version 2
From the pilot triaals it was eviident that the device hadd to be narroower than iniitially
magined. version 2 of the
t device was
w created by reducingg the width of the devicce by
im
50% to 10mm
m. The numb
ber of electro
odes in eachh arm was allso decreasedd by 50% too two,
fo
or a total of eight electro
odes. Version
n 2 of the deesign is show
wn in Figuree 2.3. This ddevice
feeatures threee layers: a conductor
c
off thin-film m
metal sandw
wiched betweeen two layeers of
in
nsulating pollymer material.

Figure 2.3: P-MEA
P
deviice, version 2. Thin-film
m metal connductor sanddwiched bettween
tw
wo layers off insulating polymer
p
mateerial.

Figuree 2.3 shows the device design for eeach layer. T
The blue layyer representts the
in
nsulating pollymer whilee the conduccting materiaal is represennted in red. The top pollymer
laayer is wind
dowed to alllow electrod
de contact w
with the carddiac tissue aand for elecctrical
co
onnections.
The device
d
is long
ger and narrrower than vversion 1 of the P-MEA with dimennsions
of ‘82mm x 10mm’.
1
Therre are four arms
a
with poorous featurees and two eelectrodes inn each
arrm for a tottal of eight electrodes in
i each P-M
MEA device.. The porouus mesh struucture
co
omprises off 12 pores, each 100µm x 200µm inn size (Figurre 2.5). The metal electrrodes
(iin red) are 70µm x 70
00µm and ru
un the entirre length off the devicee ending in large
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co
onnection paads. Each co
onnection paad is 1mm x 4mm in sizee and they aare designed to be
used in conju
unction with a spring pro
obe connectinng harness.

(aa)

(b
b)
Figure 2.4: P-MEA,
P
verssion 2 shown with separ
arated layers. (a) Top innsulating pollymer
laayer. (b) Meetal electrodee layer runniing the entirre length of the device. The label ““Top”
was
w included
d as only th
he top surface had expoosed electroodes at the location of ECT
em
mbedding.
In add
dition, the design
d
incorp
porated som
me conveniennce features for handlingg and
placement. The
T metal eleectrode layeer is used too layout chaaracters to eaasily identiffy the
ex
xposed top surface. Thee polymer laayer which pprovides struucture and bboundaries tto the
device has curved
c
inden
nted featurees (Figure 22.5) to prevvent sharp corners andd any
reesulting tearring and to aid
a the centeering of the exposed eleectrodes withhin the ECT
T. The
lo
ower end of the device has
h an elong
gated sectionn with an opening left inn its tab to handle
an
nd secure th
he device du
uring and affter tissue em
mbedding. The separaation betweeen the
fo
our arms of the device (above and below the m
mesh structuure) allows m
movement oof the
in
ndividual deevice arms within
w
the EC
CT. Figure 22.5 shows thhe (expandeed) section oof the
porous mesh structure of device.
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Figure
F
2.5: The
T porous mesh
m
section
n of the devicce. This messh section is embedded iin the
tiissue; the exp
posed areas of the electrrodes are notted by the brrighter shadee of red coloor.

d
was fabricated
f
by
y a two-massk process aand utilized polyimide aas the
The device
in
nsulator and gold as the metal
m
electro
ode. The devvices were eembedded inn the ECT whhile it
iss in gel form
m and the tisssue forms wh
hen the gel ppolymerizes.. The electriccal stimulatiion of
th
he tissue waas accomplisshed by con
nnecting an electrical sstimulator too any two oof the
ellectrodes. Various
V
experriments werre conductedd using versiion 2 of the device for acute
an
nd chronic electrical
e
stim
mulation of ECT. Durinng these expeeriments it w
was observedd that
th
he electrode material waas corroding
g and deterioorating. The metal was reacting witth the
cu
ulture mediu
um and releeasing produ
ucts into thee culture trayy resulting iin cell deathh and
co
onsequently tissue dam
mage. This was attribuuted to the higher amoounts of vooltage
reequired to ellicit a respon
nse from the ECT. The suurface area oof the pads w
was not suffi
ficient
to
o achieve eleectrical stim
mulation. Hen
nce, a furtheer change in the design oof the devicee was
reequired. Thee design waas refined based
b
on coonducted expperiments aand observattions.
Several functional and co
onvenience features
f
weree added to crreate versionn 3.
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2.3 Version 3
Version 3 is the current and final version of the P-MEA device. Figure 2.6
presents the design layout of the P-MEA device with close-up views of key sections.
Unique design features of version 3 include:
•

Width of 10 mm and length of 82 mm to allow electrical connections (2.6a).

•

Four arms to allow movement of ECT between the individual device pads (2.6a).

•

Total of four embedded electrodes in each device (2.6b).

•

Four large pads on either side of the ECT which act as return electrodes during invitro testing (2.6b).

•

Suture holes in each of the large pads to aid in-vivo suturing and contact (2.6b).

•

The top polymer layer was windowed in specific locations (unshaded red areas) to
allow electrode contact with the cardiac tissue and for external electrical
connections (Fig 2.6a).

•

Electrode dimensions are (0.09mm x 80mm); electrodes run the entire length of
the device (2.6b).

•

Each of the eight contact pads (2d) connect with one of eight small or large
electrode pads (2.6b).

•

Porosity: Each embedded electrode incorporates eight 100µm x 200µm
rectangular openings surrounding an electrode pad which is 950µm x 340µm
(2.6c).

•

Curved indented markers for easy positioning of the exposed electrodes in the
ECT (2.6c).
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(a)
(

(b
b)

(cc)

(d
d)

Figure 2.6 (a) Representaative design of a P-MEA
A device. T
The red section representts the
gold electrod
des while th
he blue repreesents the ppolyimide laayer. The feature in greeen is
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representative of an embedded ECT. (b) Blown-up view of the main device area. The
small pads were embedded inside the ECT, while the big pads are in the culture medium.
(c) Close-up view of one of the embedded pads. The porous feature is highlighted by the
8 rectangular openings on either side of the small pad. The area in shaded red indicates
the electrode portion covered by the polyimide. (d) Contact area with the connection
pads.
For making external connections spring-probe connectors were used which were
mounted on a custom board. The device was designed for use with a specific linear
arrangement of spring probes and the contact areas were designed so alignment and
interfacing are convenient. The circuit board was designed in CIRCAD and prototypes
were created. After several pilot trials and modifications, the circuit board was
outsourced for manufacturing 40 boards. The supporting board was made from 6mm
thick acrylic sheets of 12”x12” dimensions. The design was created in L-EDIT and was
used as an outline in a laser beam cutter and polisher. Figure 2.7 shows one setup of the
supporting board along with two circuit boards. Each of the circuit boards has a springprobe connector at the front end to make contact with the connecting pads on the P-MEA
device. The other end has a custom wiring harness which takes the connections to larger
board for multiple parallel connections.
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(a)

(bb)

(c)
upporting bo
oard and con
nnecting circcuit board foor making connections tto the
Figure 2.7: Su
P-MEA devicce. (a) laser--cut acrylic board,
b
(b) cirrcuit board w
with spring-probe conneectors
an
nd custom wiring harn
ness, (c) circcuit board tto run paraallel connecttions to muultiple
devices at thee same time.
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CHAPTER III
FABRICATION

3.1 Materials
The primary considerations in the choice of materials for the P-MEA devices were
(1) bio-compatibility and (2) mechanical flexibility. Since the device is embedded inside
tissue with living cells, the choice of materials had to be limited to biocompatible
materials. Biocompatibility requires that all materials are both non-toxic and nonreactive. The usage scenarios include in-vitro and in-vivo applications where the device
is required to be highly flexible while being strong enough to withstand bending and
folding, but not break or damage the electrical conductor. Other considerations required
the device design and material to be able to deliver sufficient voltage to elicit a response
from the ECT at a safe level. This should be accomplished without causing any Faradaic
reactions which could create and release unwanted compounds leading to material
corrosion and deterioration which would further lead to tissue toxicity and cell death.
[60]. In his review article, Merrill has compiled and listed an excellent table with
materials that have been used by various researchers over the years [60, Table 1, Pg.
185]. The table primarily lists materials by their classification of biocompatibility and
toxicity.
Among the insulators, polyimide is a polymer material which has both flexibility and
bio-compatibility. Polyimide is available from HD MicroSystems in liquid form suitable
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to be deposited and cured to achieve a desired thickness. The polyimide chosen for the PMEA, PI-2611, is specifically designed for microelectronic applications and has excellent
thin-film properties such as low stress, low coefficient of thermal expansion (3 ppm/°C),
high tensile strength (350 MPa), and good ductility. The insulating material has to
undergo metal deposition twice during the fabrication process and PI-2611 can withstand
it without any evident damage to the film. Cured film thickness ranges from 3µm-9µm.
The target thickness for the device, which includes a dual layer of the insulating polymer,
was 15µm-18µm. This required the final cured thickness of one single layer to be
approximately 8µm.
The most common and popular choices for thin-film metal electrodes are gold and
platinum, both noble metals. They are highly desirable for their electrical properties as
well as ductility and malleability. Platinum has been used extensively and is highly
popular as a stimulating material, more so than gold. The choice between platinum and
gold was simple logistics and economics; gold was less expensive and readily available
(at MNTC, Louisville) for the fabrication of P-MEA prototypes. Gold does not corrode
like other metals but it requires an adhesion layer because it does not adhere well to
surfaces [79]. Chrome, nickel or titanium can be used as adhesion layers for thin-film
gold depositions. In a theoretical study of metal-polyimide interfaces, Marta Ramos
compared and contrasted bonding strength and adhesion energies of chrome and nickel to
polyimide [68]. Although the calculations seem to suggest chrome as having higher
adhesion energy than nickel, P-MEA experiments showed nickel as a better adhesion
layer for gold on polyimide.
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3.2 Process Flow
F
Becau
use the minim
mum featuree size of thee P-MEA is in the micron scale ME
EMSbased microfa
fabrication teechniques weere utilized iin the class 100 cleanrooom of the M
MNTC
att the University of Louissville (Louissville, KY) tto manufactuure these devvices. The ddevice
faabrication in
nvolved a tw
wo-mask fab
brication proocess, one tto pattern thhe electrodess and
th
hen one to pattern the po
olymer layerr and open uup contact windows for tthe electrodees. A
4” silicon wafer was used
d as a supporrt structure too build the ddevices.
p
flow
w can be sum
mmarized inn three major steps: (1) depositingg and
The process
uring the firrst layer of polymer,
p
(2)) depositing and patternning the mettal electrodes and
cu
(3
3) depositing
g, curing and
d patterning the second (top) layer oof polymer. The first layyer of
th
he insulating
g polymer material
m
is not
n patternedd; the devicee is designeed such that both
laayers of the polymer aree patterned simultaneou
s
usly in the laast step. Thee second layyer of
polymer is designed
d
to cover the metal
m
layer w
which acts aas a naturall stop durinng the
polymer etch. The etch continues in other areas tto result in tthe delineatiion of the deevice.
Thus
T
the dev
vice fabricattion requires only two photomaskss. Figure 3..1 (b) show
ws the
crross-sectionaal view of the
t device fabrication
fa
pprocess (the cross-sectioon is taken aat the
ap
pproximate location sho
own by the green arrow
w lines in Fiigure 3.1 (a))). Figure 3..1 (c)
sh
hows the step-by-step flo
ow-chart.

Figure 3.1 (aa): PMEA deevice. Green
n arrow linees show the approximatte location oof the
crross-sectioniing. The dev
vice design used
u
for the eexample is vversion 3.
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(b)

(c)
Silicon Wafer

Deposit PI & Thermal Cure

Deposit Ni/Au

Lift-Off

Deposit PI & Thermal Cure

Deposit AL

Pattern AL

Etch PI

Etch AL & Clean

Release Device

Legend

SILICON

POLYIMIDE

GOLD

ALUMINUM

Figure 3.1: Fabrication process flow. (a) Left column shows the cross-sectional view of
the (cut shown by the green arrow lines in 3.1 (a)) (b) Right column shows the flowchart
for the processing steps.

28

3.3 Fabrication Process

3.3.1 Silicon Wafer Cleaning
A 4” silicon wafer was used as a handle wafer to support device fabrication.
Before commencing fabrication, the wafers were subject to a standard cleaning procedure
known as RCA clean to remove organic, ionic and metallic contamination from the wafer
surface [ref. Kern W.]. The wafers were subjected to a two-step immersion-cleaning
process in which the silicon surface was first treated to a mixture of hydrogen peroxide
(H2O2) and ammonium hydroxide (NH4OH) heated to 75℃ (removes organic particles
and contamination). The second step involved a solution of hydrochloric acid (HCL)
and H2O2 to remove ionic and metallic contamination. The wafer was then rinsed with
deionized (DI) water and blow-dried with nitrogen (N2). A dehydration bake was
performed immediately following the RCA clean process on an open hotplate at 115℃
for five minutes.

3.3.2 Depositing Polyimide
The polyimide PI-2611 is a viscous liquid stored in the manufacturer’s bottle at a
recommended temperature of -18℃ to maximize its shelf life to two years [PI-2600
Series Product Bulletin, Figure 3.2 (a)]. It is taken out and stored in small quantities at
room temperature at need. Room temperature PI-2611 was spin-coated on each wafer in
four static-dispensing steps to allow an even coating of the polyimide. The silicon wafer
was first placed on a wafer chuck in a spin-coater (Headway Research, Garland, TX).
The material is deposited on to the center of the wafer by directly dropping from the
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bottle to creaate a ‘five ceent coin’ sizzed layer. Thhe PI-2611 w
was then allowed to stabbilize
an
nd flow on the
t wafer su
urface to elim
minate any ttrapped air bbubbles (Figgure 3.2.(b)). The
deposition was
w finalized
d by spinnin
ng the waferr according to the paraameters show
wn in
Table
T
3.1.

Table
T
3.1: Sp
pin parameteers for depossition of Pollyimide PI-22611 on Si w
wafer. Two steps
arre used to sp
pread the pollyimide and evenly coat the surface.
Step

Speed (rpm
m)

Raamp Rate (rppm/s)

D
Duration (seccs)

1

500

100

10

2

1500

150

20

3

3000

1000

20

4

0

500

0

ottle stored in
i refrigeratoor. (b) Spin--coating PI-22611 on a siilicon
Figure 3.2: (aa) PI2611 bo
wafer.
w
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3.3.3 Thermaal Curing
A sofft bake wass performed at 115ºC ffor three m
minutes on aan open hottplate
mmediately following th
he spin-coatiing. This stepp removes aall residual m
moisture from
m the
im
co
oated layer of polyimid
de. Followin
ng the soft bbake, the poolyimide-coaated wafers were
th
hermally cu
ured in a high tempeerature vaccuum oven (YES-PB 6-2P-CP, Y
Yield
Engineering
E
Systems, Liivermore, Caalifornia) att 350ºC for one hour (F
Figure 3.3). The
cu
uring processs starting temperature was 50ºC w
with heatingg and coolinng ramp tim
mes of
100ºC /hour and
a a total cu
uring time of 7 hours (Fiigure 3.4). T
The vacuum environmennt was
su
ubject to dehydration
d
cycles to remove
r
oxyygen and m
moisture. Niitrogen gas was
co
ontinuously supplied acrross the surfface of the w
wafer to mainntain an inertt environmennt.

Figure 3.3: PI
P cure vacuu
um oven fro
om Yield Enngineering S
Systems. Waafers (up to 6” in
diameter) are loaded verttically and niitrogen gas fflows in a peerpendicularr direction (tto the
hamber), acrross the surfface of the wafer.
w
(Imagee source: com
mpany webssite).
ch
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Figure 3.4: Temperature profile of a seven hour thermal curing process for the polyimide
PI-2611 in a YES vacuum oven with heating and cooling ramp rates of 100℃/hour.

3.3.4 Photolithography (Mask 1)
A pattern for the electrodes was created on the polyimide surface using a
photomask and photoresist. A photomask is a glass plate with a coating of chromium
created in a laser patterning system (Heidelberg DWL 66FS) based on the design
developed in L-Edit software (Tanner EDA, Monrovia, CA). The pattern was transferred
from the mask to the wafer in a light sensitive resist via exposure to ultraviolet (UV)
light. The resist was coated on to the surface and then UV exposure (partially blocked by
the mask) enables an identical imprint to be created in the photoresist layer. This was
accomplished by loading the mask and the wafer in a mask aligner (MA/BA6, SÜSS
MicroTec AG, Garching, Germany; Figure 3.5).
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Mask
k holder

Wafeer holder

M
aligner model MA//BA6 from S
SÜSS MicrooTec AG. Thhe mask is uupside
Figure 3.5: Mask
i contact or
o close proxximity to thhe surface. T
The alignmeent is
down and the wafer is in
performed using the opticcs and computer system.. (Image souurce: companny website).

p
for th
he photoresisst was used to create thhe gold electtrodes by ussing a
The pattern
metal depossition,
liift-off process. Usually a metal patttern creatioon follows thhe path of m
ph
hotoresist ap
pplication/deevelopment and
a finally m
metal etch. A lift-off proocess reversees the
orrder of metaal deposition
n and photorresist patternning. The photoresist iss first coatedd and
developed, followed
fo
by the metal deposition. It enables the patternning of materials
without
w
using
g powerful etchants.
e
Go
old etch requuires the usee of strong cchemical etcchants
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such as aqua regia (hydrochloric acid + nitric acid) or AU-5 (potassium iodide).
Moreover these are dark in color and make the submerged sample nearly impossible to
observe. A lift-off process eliminates the etching step by creating a hanging retro edge
profile in the patterned photoresist layer. The metal is deposited on the resist; the
unwanted resist is soaked in a solvent and removed along with the unwanted metal. The
lift-off process used for the P-MEA fabrication is listed in Figure 3.6.

Spin-coat Photoresist

Soft bake (90℃, 60s)

UV Exposure (30s)

Toluene soak (60s)

Bake (90℃, 15s)

Develop photoresist
Figure 3.6: Photoresist lift-off process flow. The toluene soak hardens the top of the
resist, leaving overhanging edges at the sidewalls of the resist.
A G-line photo resist S1827 (Microposit S1800 series, MicroChem Corp.,
Newton, MA) was used to first create the pattern (using Mask 1) over which the metal
was deposited. The photoresist is spin-coated on the polyimide-coated wafer surface
using the parameters listed in Table 3.2. A resist coating of 2.7µm was obtained using
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these parameters. A soft bake was performed on a hotplate at 90℃ for 60 seconds. Wafer
and mask were loaded on to the mask aligner and exposed to UV light at a power density
of 4.5 mW/cm2 for 20 seconds. The resist was subjected to a 60-second toluene soak
(Avantor Performance Materials, Center Valley, PA) to harden the top layer of resist.
Development of the exposed resist was performed in MF-319 (Avantor Performance
Materials, Center Valley, PA) to create the desired pattern.

Table 3.2: Spin parameters for coating photoresist S1827; total time was 18.7 seconds
Step

Speed (rpm)

Ramp Rate (rpm/s)

Duration (secs)

1

500

500

0.2

2

4000

1000

10

3

0

1000

0

Table 3.2: Spin parameters for coating photoresist S1827; total time was 18.7 seconds.

3.3.5 Sputter Deposition
Sputter deposition or sputtering is a physical vapor deposition (PVD) process in
which material from a target is removed and deposited on a wafer. In sputtering, the
wafer and the target material are positioned across from one another in a vacuum
environment and a high voltage is applied across them to create a negative potential at the
target. The transport of material takes place in argon plasma where the Ar+ ions strike the
target with energy to dislodge individual atoms from the target surface which in turn are
transported on to the wafer surface. A magnet is held behind the source target to control
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th
he energy fieeld which efffectively in
ncreases the sputter pathh length and improves spputter
raates. This process
p
is also known as magnnetron sputttering [ref. Introductioon to
Microfabricat
M
tion (2010) - Sami Frranssila]. M
Metal deposiitions for thhe P-MEA were
performed ussing a DC sputtering
s
prrocess in arggon plasma in PVD 755 (Kurt J. L
Lesker
Company,
C
Pitttsburgh, PA
A, Figure 3.7).

VD 75 sputtter depositio
on system froom KJL. Thee double dooors hide the main
Figure 3.7: PV
mber on the leeft while thee controllingg computer aand power suupplies are oon the
prrocess cham
riight. The prrocess cham
mber usually contains foour 3” targetts but can bbe customized to
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un
nique needss (MNTC PV
VD75 has tw
wo 3” and oone 4” targetts). (Image source: com
mpany
website).
w
w
was held
h
upside down abovee the targetss in a revollving holderr at a
The wafer
sp
peed of 5 rp
pm. This rotaation alloweed an even c oating of thhe metal duriing depositioon. A
vacuum is creeated beforee the argon gas
g is releaseed into the cchamber at a base pressuure of
5x
x10-5 Torr. The sputter pressure waas set at 3m
mT and sputtter power was 300W ussing a
DC
D power so
ource. Nickeel was depossited for 2 m
minutes folloowed by 100 minutes off gold
deposition (F
Figure 3.8). Nickel
N
was used
u
as an aadhesion layyer to ensuree good adherrence
between the gold
g
and pollyimide layerrs. Before eaach depositioon the targett is subjectedd to a
sp
putter clean
n process by
y merely tu
urning on thhe power soource for 30 seconds w
while
sh
hielding the wafer with a shutter.

Figure 3.8: A 4” silicon wafer
w
with a sputter-coaated layer off Ni/Au on a polyimide llayer.
Note
N the faintt lines visiblle under the surface; theyy are the elecctrodes etchhed in photorresist.
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3.3.6 Lift-Offf Process
Follow
wing deposiition the waafer was theen subjectedd to a 44.1 KHz ultraasonic
gitation in acetone.
a
The resist ‘lifted
d off’ leavinng behind thhe gold layerr in the patteern of
ag
th
he Fdevice electrodes an
nd traces (Fig
gure 3.9).

Completedd lift-off.

Figure 3.9: Acetone
A
solv
vent soak forr the lift-offf process. Phhotoresist disssolves readdily in
he patterned
d photoresist was removeed along witth the metal on top of it. Note
accetone and th
th
he gold partiicles floating
g in the acettone in the leeft beaker. T
The right beaaker shows a liftoff process in
n progress with the Ni/Au
u layer partiially removeed.

A waffer with a completed lifft-off processs is shown in Figure 3.10; it show
ws the
gold electrodees formed on
n the first po
olyimide layer (version 2 of the deviice).
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Polyyimide layer

Nickel/Gold
N
electrode lay
ayer on top oof PI
g
electroodes after a llift-off proceess and DI w
water
Figure 3.10: Wafer with completed gold
g. (version 2 of the P-ME
EA shown inn fabricationn).
riinse cleaning

S
layerr of polyimid
de – soft bakke on hotplaate prior to vacuum curinng.
Figure 3.11: Second
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The second layer of polyimid
de was thenn deposited oon top of thhe gold layer and
cu
ured using the same parameters
p
as before. Figure 3.111 shows a soft bake bbeing
performed on
n an open hott plate prior to thermal ccuring in thee YES oven.

3.3.7 Aluminum Sputterin
ng
After the second layer
l
of PI was
w cured, alluminum waas sputter-deeposited on ttop of
th
he cured surfface. Sputterring was perrformed usinng the PVD775 sputter deeposition system;
sp
putter pressu
ure was 3mT
Torr, power was
w 300W aand length oof depositionn was 10 minnutes.
The
T final thicckness of th
he aluminum
m layer was approximattely 0.2µm ((shown in F
Figure
3.12). This aluminum
a
laayer was useed as a hardd mask to pprotect the ppolyimide dduring
ettching.

A
coating
c
on to
op of the cuured polyimidde layer. Thhe aluminum
m film
Figure 3.12: Aluminum
was
w used as a mask for th
he polyimidee etch.
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3.3.8 Photolitthography (M
Mask 2)
The seecond lithog
graphy step was
w similar tto the first oone (section 33.3.4) in term
ms of
materials
m
and
d processing
g. The photoresist S18827 was sppin-coated oon the alum
minum
su
urface using
g the same parameters and patternned using M
Mask 2. Afteer processing the
wafer
w
looks as
a shown in Figure
F
3.13.

Figure 3.13: P-MEA dev
vice pattern in photoresiist S1827 laayer; the ressist is seen iin the
yellow coloreed pattern ov
ver the shin
ny aluminum
m coating. Thhe PI layer is visible arround
th
he periphery of the waferr under the aluminum
a
laayer.

The patterned pho
otoresist wass used as a m
mask to etch the aluminuum film. Thee etch
was
w performeed using thee wet chem
mical etchantt, aluminum
m etch (Avanntor Perform
mance
Materials,
M
Ceenter Valley
y, PA). It comprised
c
o f 2% nitric acid, 3% aacetic acid, 80%
ph
hosphoric accid and 15%
% water. The etchant w
was heated too a temperatture of 45℃
℃ in a
beaker on an open hotplatte. The post--etch cleanedd wafer is shhown in Figuure 3.14.
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T wafer with
w the etcheed aluminum
m layer. Thiss aluminum llayer now haas the
Figure 3.14: The
pattern from Mask
M
2.

3.3.9 Polyimiide Etch
The polyimide
p
was
w etched in a Reacttive Ion Etcch (RIE) syystem (CS-1701,
Nordson
N
MA
ARCH, Conccord, CA) process
p
usinng oxygen ggas plasma at a pressuure of
50mT and po
ower of 300
0W for 20-30
0 minutes. T
The RIE proocess servedd a dual purrpose;
op
pening up th
he electrode areas on thee top surfacee of the devvice requiredd to make coontact
with
w the ECT
T and the ellectrical con
nnections, ass well as paatterning andd cutting ouut the
device. The oxygen
o
plasm
ma etched th
he polyimidee layer and stopped on tthe metal suurface
(g
gold). Howeever, the etcch continued
d along the device perrimeter to ddefine the ovverall
design and seeparate the individual devices.
d
Thee aluminum mask was sstripped afteer the
RIE
R process was
w completted; the wafeer with the patterned devvices is show
wn in Figure 3.15.
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Figure 3.15: The silicon
n wafer con
ntaining thee P-MEA deevices (verssion 2) afteer the
co
ompleted etcch process. Note
N
the ressidue on the exposed goold pads; thee shinier tracces of
th
he metal are sandwiched
d between thee two polyim
mide layers.

wed by methhanol
Devicces were cleaned using an acetone soaked soft wipe follow
(A
Avantor Perrformance Materials,
M
Ceenter Valleyy, PA). Deioonized waterr was used for a
fiinal clean. Figure 3.16 sh
hows the cleeaned P-ME
EA devices (vversion 3) onn a silicon w
wafer.
Each
E
device was
w then tested on a pro
obe station (M
MPS150, Caascade Microotech, Beaveerton,
OR)
O for electrode integritty and resistaance betweeen the proxim
mal contact ppad and the distal
ellectrodes. Th
hese values as
a well as th
hicknesses foor the deposiited layers aare reported iin the
reesults section
n.
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A devices oon a 4” siliccon wafer. T
The devices were
Figure 3.16: version 3 of the P-MEA
sq
queezed togeether to increease the num
mber of devicces to six (frrom five in vversion 2).

The devices
d
were removed fro
om the wafeer by sliding a razor bladde underneatth the
en
nd tab near the connectiion pads. On
nce a small corner lifts off, it was rrelatively eaasy to
grrab hold of the tab witth a pair of tweezers annd gently peeel off the eentire devicee. No
sp
pecial chemiicals or proccessing were required to remove the P-MEA devvices.
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CHAPTER
R IV
ELECTR
RICAL AND
D ELECTRO
OCHEMICA
AL TESTING
G

4.1 Device In
ntegrity Testiing
The devices
d
were tested for ellectrical inteegrity on a w
wafer probe sstation (MPS
S150,
Cascade
C
Micrrotech, Beav
verton, OR) after fabricaation. Each eelectrode traace was testeed for
co
ontinuity sin
nce the electrrode was lon
ng and narroow; a tiny im
mperfection dduring fabriccation
co
ould render the electrod
de line uselless. Resistaance measurrements werre taken for each
ellectrode durring the test by connectiing the meteer between tthe proximaal embedded pads
an
nd the distall connection pads (shown
n in Figure 44.1).

C
prob
be station for
fo testing ddevice electrrode integrityy and resisttance.
Figure 4.1: Cascade
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The wafer
w
was placed on the probe statioon wafer chuuck with thee small embeedded
pads visible through
t
the lens
l
optics. One
O probe w
was maneuveered into poosition and pplaced
n the gold surface
s
of th
he embedded
d pad. The ooptical assem
mbly of the pprobe stationn had
on
liimited travell and could not
n be positiioned to view
w the distal pad. Hence the second pprobe
was
w positioneed without an
ny optical aiid (Figure 4.2).

Figure 4.2: Prrobe testing the electrodes. Probe onn the left is oon the embeddded pad andd was
nderneath thee lens, whilee the probe oon the right is on the connnecting pad..
positioned un

Averaage resistancce measurem
ments across tthe lengths oof the electroodes ranged from
8.52Ω. In ad
ddition, the thickness
t
off the Ni/Au electrodes oof five (randdomly
69.45Ω to 78
hosen) devicces was meaasured using
g a Dektak pprofilometer. This resultted in an average
ch
th
hickness of 20nm
2
of nick
kel and 400n
nm of gold. An averagee thickness oof 0.4µm±0.002µm
was
w obtained
d for the elecctrode films. The therm
mal curing reesults in a poolyimide layyer of
8µm thicknesss and the do
ouble polyim
mide layer waas approxim
mately 16µm thick.
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4.2 Equivalent Electrode Model
Further evaluation of the P-MEA device was done by performing electrochemical
experiments using the same scenario as the actual application. This involved the device
transporting electrical signals from a stimulator to the ECT immersed in culture medium
(Dulbeccco’s Modified Eagle Medium (DMEM), 11965-092 (high glucose), Gibco by
Life Technologies, Grand Island, NY), which acts like an electrolyte. Since charge
transfer takes place between the electrons in the electrode and ions in the electrolyte it
was necessary to evaluate the performance of the electrodes while immersed in the
culture medium. The four small exposed electrode pads embedded within the ECT were
electrically coupled to form one common connection while the four large electrode pads
in the culture medium were coupled to form the common return connection. To evaluate
the electrochemical interface a representative equivalent circuit model needs to be used.
Several models have been proposed to approximate the electrode-electrolyte interface.
The most widely used model is a two-element model, which has resistance representing
the electrode’s polarization resistance or impedance and a capacitance in parallel with the
resistance [60-62]. The capacitance represents the charged layer at the electrodeelectrolyte interface which is caused due to the presence of a layer of charge at the
electrode surface and an equal and opposite layer of charge in the electrolyte. This double
layer of charge at the interface behaves akin to a capacitor and hence is called as the
double-layer capacitance. Each parallel combination of the resistance and capacitance
represents one set of electrodes. For the P-MEA device, the four small embedded
electrodes were referred to as the ‘Working Electrode’ (WE) and the four large electrodes
as the ‘Counter Electrode’ (CE). For the equivalent circuit model (Figure 4.3), R1 and C1
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model
m
the WE
E, and R2 an
nd C2 modeel the CE. Inn addition too these compponents theree was
a resistance RS
R which rep
presents the solution (eleectrolyte) ressistance.
4.3 (a)

T
The four largge pads
coupled toggether

The fou
ur small pad
ds
couplled together

Figure 4.3 (b))

( An ECT
T embedded with a P-M
MEA devicee. The four large pads were
Figure 4.3: (a)
oupled togetther (externaally) and the four small eembedded paads were couupled
ellectrically co
to
ogether. (b) Equivalentt circuit model
m
for thhe P-MEA device in culture meedium
(D
DMEM). R1
1 & C1 repreesent the inteerface betweeen the embeedded pads & DMEM; R
R2 &
C2
C represent the interfacce at the laarge pads & DME, andd RS represeents the sollution
reesistance.
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Charge transfer between the electrode and electrolyte can occur in three primary
ways, non-faradaic charging and discharging, reversible faradaic reactions, and
irreversible faradaic reactions. Of the three mechanisms, the first two are highly desirable
while irreversible faradaic reactions are not due to the risk of electrode corrosion and
tissue damage [60].
4.3 Electrochemical Impedance Spectroscopy (EIS)
A safe operating limit for the device-electrolyte interface can be determined by
assessing the performance of the electrodes in culture medium (DMEM) using
Electrochemical Impedance Spectroscopy (EIS). EIS is an excellent tool for analyzing
electrode performance in an electrolyte and can be used to determine presence or absence
of irreversible reactions [24-27]. Impedance Spectroscopy, as the name suggests is the
measurement of impedance of an electrical circuit over a range or spectrum of
frequencies [70-72]. Electrochemical Impedance Spectroscopy is an analysis tool wherein
a sinusoidal signal is applied to an electrochemical system or cell, and the current flowing
through the cell is measured. The amplitude of the signal is kept very small; between
1mV-10mV, to ensure a pseudo-linear response from the cell. The frequency range is
typically varied from 1mHz to 1MHz. Due to the very small input signal frequencies, the
EIS tests often take hours to complete the entire spectrum. To evaluate the performance
and to determine operating limits, a DC component is applied with the AC signal and the
voltage is varied over a desired testing range [70-73].

The input voltage and current response can be represented by the following equations:

( )=

sin(
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)

Eq. 4.1

( )=

sin(

+ )

Eq. 4.2

where θ is the phase shift of the signal. Using Ohm’s law, the impedance can be written
as;
( )

=

∴

( )

(

=

(

(

=

)

Eq. 4.3

)

)

(

Eq. 4.4

)

In the complex plane this equation can be represented as;

( )=

(

+

)

Eq. 4.5

Equation 4.5 for the impedance contains real (Z’) and imaginary (Z”)
components. The imaginary component is due to the capacitive-like behavior at the
electrode-electrolyte interface. Plotting both values in a chart gives us a Nyquist plot for
the system. For a simple equivalent circuit, similar to the one shown in figure 4.3 (b), this
results in a semi-circle (shown in Figure 4.4). This circuit is also called as a single time
constant circuit, as is evident from the one semi-circle in the plot. Multiple interfaces
would result in multiple time constants and multiple semi-circles. Bode plots are used to
view frequency and phase angle information. In a typical Bode plot, the magnitude and
phase angle of the impedance vector is plotted against the frequency input. The phase
plot indicates the behavior of the double layer capacitance at the interface. At low
frequencies the ions in the electrolyte diffuse to the interface at a finite rate hence the
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Nyquist plot has a linear response at low ω. RP shown in the figure indicates the
polarization resistance of the electrode under investigation. It can be simply defined as
the ability of the electrode to resist current flow. The higher the resistance, the lower the
rate of corrosion and deterioration. So a semi-circle with a higher radius is always
desirable in the Nyquist plot.
Low ω

Z”

RP
Z’

High ω

Figure 4.4: Representative Nyquist plot for a single time constant interface. Nyquist plots
don’t contain any frequency information, they can only represent impedances.

The results from EIS are collected and used in a software simulator to generate
values for the components in the equivalent circuit. The relationship between the
impedance and the circuit components can be given by;

( )=

+

51

Eq 4.6

Potenttiostat/Galvaanostat Mod
del 273A (P
Princeton Appplied Reseaarch, Oak R
Ridge,
TN)
T was useed to collectt EIS data and
a ‘EIS Sppectrum Anaalyser’ (freeeware, Belarrusian
State Universsity, Minsk,, Belarus) to
o analyze aand simulatee the perforrmance of thhe PMEA-S
M
electrrodes in DM
MEM. Experiimental setupp is shown iin Figure 4.77.

Figure 4.5: Model
M
273A
A, Potentiosstat/Galvanoostat (Princeeton Appliedd Research, Oak
Ridge,
R
TN); used
u
for the EIS experim
ments and meeasurements.

Figure 4.6: ‘E
EIS Spectru
um Analyserr’ is a free ssoftware avaailable from Belarusian State
University
U
for EIS analyssis.
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Figure 4.7: Experimental
E
l setup for EIS
E and othher electrochhemical testss. The P-ME
EA is
being tested for
f electroch
hemical perfo
ormance in cculture mediium.

Figuree 4.8 (a) sho
ows the Ny
yquist plot fo
for the EIS aanalysis of tthe individuual PMEA-S
M
electtrodes in DM
MEM. This Nyquist chaart plots thee real impeddance compoonent
(Z
Z’) against the imaginaary impedan
nce (Z”). Thhese curves can be useed to predicct the
prresence or absence of irreversible reactions. Electrode impedance comes from
m the
reesistance and
d capacitancce comprisin
ng the electrrode-electrollyte interfacee. The imagginary
co
omponent iss contributed
d by the capaacitance whicch has a freqquency depeendent impeddance
defined by:

=
where
w

is the capacitiv
ve impedancee (Ω),

E
Eq 4.7
is th
the value of the capacitaance (F), andd

is

th
he angular frrequency deffined as:

=2
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E
Eq 4.8

Imaginary Impedance -Z" (Ω)

4E+6

3E+6

2E+6

0.010V
0.1V

1E+6

1V
2V
1E+0
1E+0

1E+6

2E+66

3E+
+6

Reaal Impedancee Z' (Ω)
30000

Imaginary Impedance -Z" (Ω)

25000

0.010V
0.1V

20000
1V
2V
15000

10000

5000

0
0

(b)

5000

100000

15000

200000

25000

Real Impedannce Z' (Ω)

Figure 4.8 (aa): Nyquist plots
p
for ind
dividual EIS tests on P--MEA-S in D
DMEM meddia at
a 2 volts. Note
N the dow
wnward sift in the EIS pplot at 2 voltts consistentt with
0.01, 0.1, 1, and
EIS plot at 2 volts.
irrreversible reeactions. (b)) Expanded scale of thee individual E
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From eq. 4.7 it can be seen that as frequency increases the impedance decreases
and vice-versa. Plotting the impedance values in the Nyquist Plot results in the curve
resembling an incomplete semi-circle. The greater the radius of the semi-circle, the
higher the charge-transfer resistance. The semi-circle is the consequence of a single timeconstant circuit. This kind of circuit can be represented by the equivalent model (Figure
4.3 (b)).
For P-MEA voltage ranges of 0.01V, 0.1V and 1V, the imaginary component
value was high which is attributable to the capacitive behavior of the double layer. The
closer the interface behaves akin to a capacitor, the higher the value of the Z”. The
impedance values obtained for the 2V signal are so extremely small compared to the
other voltages. Figure 4.8 (b) shows the high frequency range of the Nyquist plots
wherein the low performance of the electrodes at 2V is evident. These are indicative of
the presence of faradaic reactions that may result in electrode corrosion and cause
damage to the tissue [24, 63-67].
In capacitors, there is a phase difference between voltage and current where
voltage lags current. In an ideal capacitor, this phase shift is 90°. The phase plots of the
EIS analysis are shown in Figure 4.9. For input voltages of 0.01V & 0.1V the electrodes
displayed behavior very close to an ideal capacitor for frequencies between 1Hz to 1KHz.
For the 1V signal the low frequency phase shift angle was initially lower. However, the
2V phase plot displayed a non-ideal, small phase shift. The phase plots indicate that the
electrode-electrolyte interface behaved akin to a capacitor at the desired operating
frequencies. Thus it can be concluded that during electrical stimulation the charge
transfer takes place due to capacitive/non-faradaic reactions.
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ndividual EIS phase plotts for P-MEA
A-S in DME
EM media att 0.01, 0.1, 11, and
Figure 4.9: In
2 volts. Notte the downw
ward sift in the phase pplot at 2 voltts consistentt with the looss of
caapacitive perrformance.

The EIS data
d
was anaalyzed and ffitted to the chosen moddel using an ‘EIS
Spectrum An
nalyzer’ (Tab
ble 4.1). Thee elements R
R1 and C1 reepresent the WE, R2 annd C2
which displaays how clossely the inteerface
reepresent the CE, and ‘η'' is a correcttion factor w
reesembles a capacitor.
c
R1
1 also represents the elecctrode polariization resisttance ‘RP’, w
which
in
ndicates the electrode’s ability
a
to ressist degradattion [57]. Iddeally, the vaalue of R1 shhould
be as high ass possible. For input voltages
v
of 0.01V, 0.1V
V & 1V, vaalues of R1 were
co
onsistently high,
h
represeenting favorable device performance. Howeverr, data at 2V
V was
co
onsistent wiith electrodee deterioratio
on due to thhe low polarrization resiistance valuee. R2
an
nd C2 were consistent accross all voltage ranges.
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The EIS data and fitted model values indicate that the P-MEA electrodes should
be able to function within the range of 1V without causing cell or tissue damage.

Table 4.1: Equivalent circuit parameters for an idealized P-MEA. R1 & C1 form the
working electrode (small pads), R2 & C2 form the counter electrode (large pads) and Rs
is the solution resistance.

Vin

RS

R1

R2

C1

η1

C2

η2

(V)

(Ω)

(Ω)

(Ω)

(F)

(%)

(F)

(%)

0.01

2.46E+02 2.22E+06

1.21E+03

3.14E-07

0.88

2.27E-06

0.73

0.1

2.59E+02 4.30E+06

1.10 E+03

3.28E-07

0.88

1.01E-06

0.81

1

2.95E+02 1.57E+06

1.86 E+03

2.57E-07

0.93

7.73E-06

0.88

2

2.13E+02 5.37E+03

1.01 E+03

2.31E-07

0.67

2.14E-05

0.60
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CHAPTER V
ENGINEERED CARDIAC TISSUE

5.1 Cell Isolation and Implant Creation
Engineered Cardiac Tissue (ECT) was created from cardiac cells isolated from
embryonic chick hearts. Cells were derived from embryonic chick ventricles to construct
each ECT as previously published by Tobita [40]. Fertile White Leghorn chicken eggs
were incubated in a forced-draft, constant-humidity incubator until Hamburger-Hamilton
(HH) stage 31 (day 7 of a 21-day incubation period). The embryos were removed from
the eggs and the heart was separated to excise the ventricles (Figure 5.1). Excised
embryonic ventricles were enzymatically digested by using 2mg/ml of collagenase type II
followed by 0.05% trypsin-EDTA solution (Invitrogen, Carlsbad, CA). Isolated cells
were preplated (filtering process) for 1 hour to reduce the non-cardiac cell population,
large debris, and red blood cells. The isolated cells were then cultured on a gyratory
shaker (60–70 rotations/min) for 24h to re-aggregate viable CMs. Approximately (3x106)
cells/ml were mixed with acid-soluble rat-tail collagen type I (Sigma, St. Louis, MO) and
matrix factors (Matrigel, BD Science, Franklin Lakes, NJ).
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(aa)

(b
b)
Figure 5.1: (aa) Embryos being
b
remov
ved from ferttile day-7 inccubated chicck eggs. (b) H
Heart
ex
xcised from day-7 embry
yos.
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The following cell/matrix mixture was made:
1) Isolated cells were suspended within a standard culture medium (Modified
Dulbecco’s Essential Medium, Invitrogen) containing 20% FBS (Invitrogen).
2) Acid-soluble collagen type I solution (pH 3) was neutralized with alkali buffer (0.2
M NaHCO3, 0.2 M HEPES, 0.1 M NaOH) on ice.
3) Matrigel (17% of total volume, BD Sciences) was added to the neutralized
collagen solution.
4) Cell suspension and matrix solution were gently mixed. The final concentration of
collagen type I was 0.67 mg/ml.
Cylindrical-shaped ECT were constructed using a collagen type I-coated silicone
membrane culture plate (Tissue Train, Flexcell International, Hillsborough, NC) and
FX-4000TT system (Flexcell International). The center of the Tissue Train culture plate
silicone membrane was deformed by vacuum pressure to form a 20mm x 2mm trough
using a cylindrical loading post (Tissue Train and FX-4000TT). The P-MEA device was
then positioned across the vacuum-formed trough with the small exposed electrodes
located directly above the trough (Figure 5.2 (a&b)). Approximately 200 µl of cell/matrix
mixture was poured into the trough (Figure 5.2 (b)) and the composite structure was then
incubated for 120 minutes in a standard CO2 incubator (37°C, 5% CO2) to form a
cylindrical-shaped construct. Both ends of the construct were held by anchors attached to
the Tissue Train culture plate (Figure 5.2 (c)). Once the ECT containing the P-MEA
device solidified, the vacuum pressure was gradually released (Figure 5.2 (d)). The
culture plate well was then filled with a growth medium containing 10% FBS and 1%
chick embryo extract (SLI, Horsted Keynes, UK), and the ECT construct floated within
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th
he growth medium
m
witth end attacchments to tthe Tissue Train plate (Figure 5.22 (e).
Culture
C
mediu
um was chan
nged every other
o
day forr the duration of in vitro culture.

Figure 5.2: (aa-d) (clockw
wise from top
p left): (a) Poositioning thhe P-MEA ddevice (versiion 2)
in
n a tissue culture plate. (b)
( Culture plate
p
on the ttissue train bbase plate. (c) Depositinng the
ch
hick cardiacc cell derived
d ECT gel construct.
c
(dd) The chickk ECTs afterr polymerizaation,
note the vacu
uum-created
d trough in the
t empty w
wells. (e) (V
Version 3) P--MEA embeedded
ECT
E
filled wiith culture medium
m
and an
a ECT withhout an embedded P-ME
EA.
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5.2 Electrical Stimulation
The ECT samples were divided into three groups and named accordingly;
[1] Control (had no embedded P-MEA)
[2] Sham (were embedded with P-MEA, no chronic electrical stimulation)
[3] P-MEA-Paced (embedded with P-MEA, chronic electrical stimulation).
The electrical stimulation experiments consisted of two separate but related
protocols; chronic pacing and acute pacing. An isolated programmable stimulator from
Coulbourn Instruments (model A13-65, Lehigh Valley, PA) was used to generate 1V
amplitude, biphasic pacing pulses with a pulse width of 1ms duration for both, positive
and negative pulses (Figure 5.3). The acute pacing protocol was used to determine
maximum pacing rates and minimum threshold capture voltages on days 3, 5, 7 & 10 of
culture. The applied input frequency was 2Hz, which translated to 120 beats per minute
(bpm). The minimum threshold voltage was determined as the lowest voltage required to
elicit a response of 120BPM from the ECT. Then the input voltage was fixed at 1V and
the frequency was increased in small steps above 2Hz. The tissue response was noted for
every stimulus until the tissue was no longer able to capture the external stimulus to
determine the maximum capture rate. Chronic pacing was initiated on day 3 of culture
using a 1V, 2Hz, biphasic stimulus and applied continuously from culture day 3 to day
10. The P-MEA-paced ECTs were subject to both, chronic as well as acute pacing while
the sham ECTs were only subject to acute pacing on the same culture days . Intrinsic beat
rates for all three groups were observed and recorded on days 3, 5, 7 & 10. A total of 60
samples were tested, including 25 P-MEA-paced, 25 controls and 10 shams. ECTs which
had diminished contraction capability (due to cell-cell coupling or other factors) were

62

discarded and not included in the report. ECTs that did not have data for all four days
were not included as well. In addition, some ECTs suffered from contamination which
resulted in cell death and tissue necrosis; these were not included in the data reported.

Day 3

Day 5

Day 10

Day 7

Acute Pacing

1V

2µs
1ms

Figure 5.3: The pacing protocol and the electrical stimulus applied across the ECT.
Biphasic pulse of 1ms (negative and positive each) with a 2µs pulse gap. Initial
stimulation frequency was 2Hz and was varied depending on the experiment.

Table 5.1 (a): Intrinsic beat rates for Control ECTs (all values in bpm).
Sample No.

Day 3

Day 5

Day 7

Day 10

1

56.00

46.00

48.00

48.00

2

40.00

56.00

50.00

80.00

3

34.00

36.00

36.00

36.00

4

48.00

64.00

58.00

58.00

5

50.00

56.00

36.00

34.00

6

58.00

68.00

60.00

44.00

Average

47.67

54.33

48.00

50.00

Std. Dev.

9.24

11.76

10.35

17.06

Std. Error

±3.77

±4.80

±4.23

±6.97
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Chronic
Pacing

Table 5.1 (b): Intrinsic beat rates for Sham ECTs (all values in bpm).
Sample No.

Day 3

Day 5

Day 7

Day 10

1

16.00

56.00

56.00

54.00

2

68.00

68.00

52.00

62.00

3

46.00

36.00

44.00

42.00

4

72.00

52.00

32.00

76.00

5

38.00

86.00

50.00

44.00

6

68.00

68.00

50.00

54.00

Average

51.33

61.00

47.33

55.33

Std. Dev.

22.08

17.05

8.45

12.50

Std. Error

±9.01

±6.96

±3.45

±5.10

Table 5.1 (c): Intrinsic beat rates for P-MEA-paced ECTs (all values in bpm).
Sample No.

Day 3

Day 5

Day 7

Day 10

1

72.00

66.00

88.00

92.00

2

30.00

48.00

46.00

72.00

3

68.00

74.00

88.00

74.00

4

68.00

34.00

38.00

8.00

5

68.00

20.00

52.00

12.00

6

58.00

60.00

58.00

10.00

7

74.00

64.00

66.00

64.00

8

30.00

54.00

70.00

66.00

9

24.00

68.00

74.00

82.00

10

72.00

58.00

62.00

60.00

11

74.00

64.00

66.00

66.00

12

22.00

36.00

76.00

74.00

13

48.00

42.00

72.00

74.00

Average

54.46

52.92

65.85

58.00

Std. Dev.

20.74

15.91

14.84

28.55

Std. Error

±5.75

±4.41

±4.12

±7.92
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Table 5.1 lists the intrinsic beat rates for control (n=6), sham (n=6) and P-MEApaced (n=13) ECTs. Comparing the data from the table, it was evident that embedment of
the P-MEA device does not cause any adverse effects in the contraction of the ECT. In
fact, the reverse was true, since the intrinsic beat rates were higher in nearly all cases.
The intrinsic beat rates obtained were higher for sham and P-MEA-paced ECTs
compared to control ECT by an average value of 8bpm (Figure 5.4). This could be
attributed to the increased stiffness as a result of the tissue encapsulation around the PMEA. The values of control and sham ECTs were similar with the shams having higher
values. The P-MEA-paced ECTs varied significantly on day 7, an effect that can be
attributed to the chronic electrical stimulus being applied to the tissue.
Intrinsic Beat Rates
70.00

Beats Per Minute

60.00
50.00
40.00
Control

30.00

Sham

20.00

Sensor-Paced

10.00
0.00
Day 3

Day 5

Day 7

Day 10

Day of Measurement
Figure 5.4: Chart comparing intrinsic beat rates for all three groups. P-MEA embedded
ECTs have higher beat rates than control ECTs.
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Table 5.2: Maximum pacing rates for P-MEA-paced ECTs (all values in bpm).
Sample No.

Day 3

Day 5

Day 7

Day 10

1

272.00

352.00

428.00

286.00

2

316.00

286.00

222.00

250.00

3

240.00

316.00

352.00

300.00

4

286.00

334.00

352.00

375.00

5

352.00

352.00

352.00

333.00

6

232.00

210.00

274.00

232.00

7

180.00

300.00

274.00

274.00

8

300.00

261.00

262.00

250.00

9

180.00

316.00

316.00

261.00

10

300.00

316.00

316.00

286.00

11

300.00

316.00

316.00

286.00

12

274.00

334.00

354.00

316.00

13

274.00

376.00

354.00

316.00

Average

269.69

313.00

320.92

289.62

Std. Dev.

50.31

42.95

53.45

38.98

Std. Error

±13.95

±11.91

±14.82

±10.81

Maximum Pacing Rate
350.00
Beats Per Minute

300.00
250.00
200.00
150.00
Max Rate

100.00
50.00
0.00
Day 3

Day 5

Day 7

Day 10

Day of Measurement
Figure 5.5: Chart showing maximum pacing rates of chronically stimulated ECTs. Max
rates peak at day 7 and decline thereafter.
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Table 5.3: Minimum threshold voltages (in volts) for P-MEA-paced ECTs at 120bpm.
Sample No.

Day 3

Day 5

Day 7

Day 10

1

0.60

0.60

0.50

0.70

2

0.40

0.50

0.50

0.60

3

0.40

0.30

0.35

0.50

4

0.30

0.25

0.35

0.45

5

0.25

0.40

0.35

0.35

6

0.30

0.30

0.35

0.40

7

0.50

0.30

0.25

0.30

8

0.25

0.40

0.40

0.30

9

0.30

0.40

0.35

0.30

10

0.40

0.40

0.40

0.50

11

0.30

0.30

0.35

0.40

12

0.30

0.50

0.40

0.40

13

0.20

0.50

0.30

0.30

Average

0.35

0.40

0.37

0.42

Std. Dev.

0.11

0.11

0.07

0.13

Std. Error

0.03

0.03

0.02

0.03

Threshold Voltage
0.50
Voltage (V)

0.40
0.30

0.40
0.35

0.42
0.37

0.20
0.10
0.00
Day 3

Day 5

Day 7

Day 10

Day of Measurement
Figure 5.6: Minimum threshold voltage for ECT capture at 120bpm; well below 0.5V.
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The conclusive evidence of functionality of the P-MEA can only be determined
from the ability of the device to stimulate, pace, and capture live tissues. Successful and
consistent stimulation of tissues was accomplished using the P-MEA device with
voltages ranging from 0.35V to 0.42V. Compared to voltages used by other research
groups [], the obtained average threshold voltage of 0.4V (using the P-MEA) was much
lower than the water electrolysis voltage and much lower than the target of 1V (Table 5.3
& Figure 5.6). This results in a huge advantage over existing methods in terms of stability
of the culture medium and tissue contamination due to byproducts because of higher
voltages. Maximum pacing capture rates follow an increasing trend with the highest
values reached on day 7, which align well with the highest rates of intrinsic contraction
also recorded on day 7. The tissue seems to be maturing and reaching a peak at or around
day 7 of tissue culture.

5.3 Histological and Immunofluorescence Staining
Histological staining and analysis was performed on ECT samples after the end of the
10-day culture period. Day 10 ECT samples were fixed with 4% paraformaldehyde at
room temperature for 15 minutes and embedded in paraffin blocks. 4µm serial sections
were cut longitudinally for histological staining. Hematoxylin-Eosin (HE) staining was
performed and light micrographs were taken using Nikon Eclipse E600 microscope. The
images were captured by SPOT color camera operated by Spot Advance software. ECT
slides were treated with 0.1 M Glycine and 0.5% Triton X-100 for 30 minutes at room
temperature after slides were de-waxed, hydrated and rinsed in 1xPBS for three times. 5Ethynyl-2'-Deoxyridine (EdU) (a marker for cell proliferation) staining was performed
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according to Click-iT EdU Imaging Kits protocol (Invitrogen, C10339), then mouse
monoclonal anti-Troponin T (Thermo, Cat# Ms-295-p0) 1:400 in 1%BSA was applied to
the tissue sections overnight, followed by Alexa Fluor 488-conjugated donkey anti mouse
1:400 (Life Technologies). Slides were mounted with ProLong® Gold Antifade Reagent
(Life Technologies). Immunofluorescent images were collected using (1) a Nikon Eclipse
E800M microscope with dry 10x, 20x, 40x Plan Fluor objective lens with 0.75 NA and
Qlympus DP72 camera to generate images with a 1360x1024 pixel density, or (2) a
Nikon Eclipse Ti Confocal System attached to a Nikon Ti-E inverted microscope
platform and Nikon Plan Apo 60x oil DICH objective lens with 1.4 NA to capture images
with a 2048x2048 pixel density. 10 regions per section were imaged in a blinded fashion
and analyzed using NIH ‘Image J’ software to count TnT and EdU positive cells to assess
cell number, identity, and proliferation rates. The software was used to perform manual
counting of cell nuclei, identify cardiomyocytes and proliferating cells. In addition,
counting was performed using an algorithm written by Will J. Kowalski [originally
published by Xu, F., Beyazoglu, T., Hefner, E., Gurkan, U.A., and Demirci, U. (2011)].
Figure 5.7 (a-i) shows representative histologic samples. ‘Control’ ECTs did not have
embedded P-MEAs, ‘Sham’ ECTs (P-MEA Non-Paced) had non-stimulated embedded
devices, and ‘P-MEA Paced’ had stimulated P-MEA. The physical shape of the control
ECT was cylindrical with the ends being splayed and nearly flat as they grab hold of the
tabs. ECTs were cylindrical between the device arms and splayed and flat immediately
adjacent to the embedded pads. The tissue was sliced longitudinally and 10 random areas
of each section were examined. The control samples had myocardial tissue with
cardiomyocytes (CM) predominantly aligned along the longitudinal axis. The sham and
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P-MEA-paced ECT cardiomyocytes were aligned according to the preferential electric
field generated by the applied electrical stimulus. Since there were four embedded pads
and four external pads for the return electrode the electric fields are varied. Cardiac
Troponin-T (TnT) staining identified myofibers in the tissue aligned along the
longitudinal tissue axis in all three groups. DAPI images showed the total cell nuclei
(blue color) and the merged image shows TnT with DAPI and 5-Ethynyl-2'-Deoxyridine
(EdU). Cell counts indicated that an average of 76 ± 2% of the cells were cardiac vs. 24 ±
2% non-cardiac. Cardiac cell proliferation was found to be very low; Control 2 ± 1%
(n=4), Sham 5 ± 2% (SE) (n=4), and P-MEA Paced 1 ± 0% (SE) (n=8). Electrical
stimulation of ECT (created from embryonic cells) had negligible effect on cell
proliferation in the tissue.

70

(a)

Cardiac Trooponin-T

(b)

DAPI

(c)

Merged withh EdU

Figure 5.7 (a-c): ECT my
yofiber cellu
ular distributtion for Conntrol ECT att day 10. Caardiac
Troponin-T
T
(TnT-Green)
(
). Nuclei (D
DAPI-blue) . Proliferatting cells (E
EdU – red). (all
im
mages at 40x
x magnificattion, scale baar representss 50µm).
71

(d)

Cardiac Trooponin-T

(e)

DAPI

(f)

M
Merged withh EdU

d-f): ECT myofiber
m
celllular distribuution for Shham ECT at day 10. Caardiac
Figure 5.7 (d
Troponin-T
T
(TnT-Green)
(
). Nuclei (D
DAPI-blue) . Proliferatting cells (E
EdU – red). (all
im
mages at 40x
x magnificattion, scale baar representss 50µm).
72

(g)

Cardiac Trroponin-T

(h)

DAPI

(i)

M
Merged withh EdU

Figure 5.7 (g
g-i): ECT myofiber
m
celllular distribuution for P-M
MEA-pacedd ECT at daay 10.
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C
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ponin-T (TnT
T-Green). Nuclei
N
(DAP
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5.4 Contractille Force Measurement
Beatin
ng and contrraction in a tissue
t
generaates force thhat can be m
measured andd used
ass an evaluaation markerr for tissue maturation. Contractile force meaasurements were
performed on
n the ECT using prev
viously publlished methhods []. The specimenn was
trransferred to
o a dissection
n chamber fiilled with Tyyrode solution containinng (in mM) 119.8
NaCl,
N
5.4 KC
Cl, 2.5 CaCll2, 1.05 MgC
Cl2, 22.6 NaaHCO3, 0.422 NaH2PO4, 0.05 Na2ED
DTA,
0.28 ascorbicc acid, 5.0 glucose,
g
and 30 2,3-butaanedione monoxime (BD
DM), gassedd with
C 2 (pH 7.4
4). The ECT
T was excisedd by severinng the P-MEA
A where it eexited
95% O2-5% CO
he ECT, leav
ving only th
he embedded
d pads in thee ECT (Figuure 5.8). Duuring a 30 m
minute
th
eq
quilibration period, the construct
c
waas field-stimuulated with a signal freqquency of 2 Hz at
5V
V (Aurora Scientific).
S
The
T segmen
nt length of the tissue w
was graduallly increasedd until
to
otal force reaached maxim
mum (Lmax).. The externnal diameterss of the tissuue at each sttretch
in
ncrement weere recorded by using a video
v
microsscopy system
m (SM-3T, S
Single Arm B
Boom
Stand Trinoccular Micro
oscope, Am
mscope, Irvinne, CA).

At each ppacing frequuency

measurement
m
ts were takeen for activee force at Lmax and passsive force aat Lmax. Daata is
reeported as mean
m
± SE (sttandard error).

Figure 5.8: A P-MEA em
mbedded ECT under forcce measurem
ment. The reemnants of tthe PMEA
M
can be seen in the still-embedded pads in the ECT. T
The left hookk is attachedd to a
fo
orce transduccer and the right
r
anchor is movable tto stretch the ECT.
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Figure 5.9 shows the active and total force generated by the ECT paced at 2Hz
and 4Hz. Active stress can be calculated by dividing the recorded values with the CrossSectional Area (CSA) of the tissue as long as the geometry of the ECT is cylindrical.
However, deformation of the ECTs was noted at the sites of P-MEA implantation such
that CSA cannot be accurately determined (Figure 5.8). Higher total force was recorded,
but similar active force generated by the sham and P-MEA-paced ECTs versus control
ECTs. Average total force generated by control, sham and P-MEA-paced ECTs was
[1.78mN ± 0.22mN (SE) for 2Hz, 1.70mN ± 0.22mN (SE) for 4Hz]; [2.45mN ± 0.31mN
(SE) for 2Hz, 2.38mN ± 0.31mN (SE) for 4Hz]; [2.48mN ± 0.27mN (SE) for 2Hz,
2.40mN ± 0.27mN (SE) for 4Hz] respectively. The higher total force in the P-MEA
embedded ECTs may be due to increased ECT stiffness due to the presence of the PMEA or to changes in the ECT material properties in response to chronic pacing.
Electrical stimulation seems to have had a negligible effect on the force generation by the
ECT. Additional experiments are required with variations in the number of embedded PMEA arms and distance between P-MEA arms to determine a direct effect of embedded
P-MEAs on ECT material properties.

3.00
2.50

Passive

3.00

2Hz

Active

2.50
0.55

0.47
Force (mN)

Force (mN)

1.50

0.47

1.00

0.43

1.50

0.35

0.33

1.00
0.50

0.50
0.00

Passive

2.00

2.00

4Hz

Active

1.31
Control

1.90

2.01

0.00

1.37
Control

P-MEA Non-Paced P-MEA Paced

1.95

2.05

P-MEA Non-Paced P-MEA Paced

Figure 5.9: ECT force recordings. Passive and active total force generated by the ECT
paced at 2 and 4 Hz (all force values in mN).
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CHAPTER VI
CONCLUSION

6.1 Device success and shortcomings
A novel device capable of low-voltage electrical stimulation of engineered cardiac
tissue has been designed, fabricated, and validated. The primary advantage of this device
is the ability to succesfully stimulate ECT at a voltage of 0.5V, which is 10 times lower
than current methods. The low voltage minimizes any undesirable oxidative by-products
in the culture environment or cell injury. In addition, a number of features relevant to in
vitro as well as in vivo applications have been incorporated. The device was shown to be
thin and flexible enough for embedment and robust enough to accomplish tissue capture
over a period of several days (primary hypothesis proven, corollary 1 & 2).
The P-MEA device has undergone three major transitions during its development
(Figure 6.1). version 1 was used to determine physical dimensions and drawbacks and
contained no electrodes; version 2 was designed with electrodes and used for embedment
and stimulation. One major flaw with version 2 was its inability to stimulate at a low
voltage. This was due to the method of stimulus application. The two outer arms (two
electrodes each) were used as the working and return electrodes for delivering the
stimulus. The higher voltages (3V) required to elicit a response caused electrode
deterioration and resulted in undesirable byproducts being released into the culture
medium, which in turn resulted in cell death and tissue damage as shown in Figure 6.2.
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(aa)

(b)
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Figure 6.1: Evolution
E
off the P-MEA
A design ovver three maajor iterationns (not to sccale);
(aa) version 1, (b) version 2, (c) versio
on 3.
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Figuree 6.2: Elecctrode deteerioration inn version 2 of P-ME
EA; undesiirable
byproducts releassed into the medium leeading to ceell death andd tissue neccrosis
(encirrcled dark/sh
hadowed region).
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Version 3 of the P-MEA was developed to overcome the problems caused by
version 2. This included a change in the design as well as the stimulation philosophy.
Instead of using the embedded pads as return electrodes, a change was made to separate
and reposition the return electrodes outside the ECT. This major change allowed an
increase in the area of the electrodes which resulted in a decrease in the required voltage.
version 3 of the P-MEA has lasted for a duration of 2 weeks continuous in-vitro
application without any corrosive effects (specific aim 1 accomplished).
The fabrication process flow was developed and refined over the evolution of the
design to obtain a high yield of devices. This process is now transferred to a
manufacturing foundry (MNTC, Louisville) (specific aim 2 accomplished).
Electrochemical characterization was performed on the P-MEA by conducting
electrochemical impedance spectroscopy experiments. The data generated during these
experiments was analyzed and computed using a simulation software to generate element
values for an equivalent electrical model (specific aim 3 accomplished).
Histological staining and force measurements did not reveal any substantial
differences between the paced ECT and non-stimulated controls. Cardiac cell
proliferation was found to be very low in stimulated ECT. Force measurements for
embedded ECT were higher than control ECT but with negligible differences between
stinulated and non-stimulated. Thus the conclusion is that electrical stimulation did not
have any appreciable effect on the functional maturation of embyronic cell cardiac tissue.
(corollary 3 disproven/negative).
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One of the drawbacks of the P-MEA is that it’s embedded nature caused minor
changes in ECT form and structure. Since the ECT was separated by the P-MEA device
arms, it caused a ‘splayed’ effect between each pair of the arms. Without a disruption, the
ECT compacts physically to result in a cylindrical structure. The embedment resulted in a
thinning of the ECT; instead of a circular cross-section it caused a flatter and wider
physical layout. In several ECT, thinning associated with P-MEA embedding resulted in
the inadvertant removal of the P-MEA out of the ECT (Figure 6.3).
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6.2 Current and Future Work
Ongoing applications of the P-MEA include using the P-MEA to stimulate
cardiomyocyte (CM) maturation in stem cell derived ECT where CM maturation is
known to be delayed. Some research groups have shown maturation of stem cell derived
tissue using electrical stimulation. Currently, the P-MEA is being used for in-vitro
stimulation of two types of stem cell ECT; (1) Human Induced Pluripotent Stem (IPS)
cells and (2) Mouse Adipose Stem Cells (ASC). Observed stimulation voltages range
from 0.9V-3V for the IPS ECT and 0.5V-1V for ASC ECT.
Current and future work involves implantation of P-MEA embedded ECT onto
the rat epicardium to test the ability to electrically couple implanted ECTs to the recient
myocardium. Once the P-MEA device embedded within the ECT becomes electrically
coupled to the underlying epicardial tissues, the device should facilitate electrical pacing,
mapping, and recording experiments. Pilot in vivo P-MEA embedded ECT implantation
trials have been carried onto the surface of the adult rat myocardium similar to previously
published method for ECT mediated cardiac repair [28] with the P-MEA device sutured
on to the surface of a rat heart for a period of three weeks (Figure 6.4). High resolution
ultrasound imaging during pacing protocols confirmed the electrical coupling of the PMEA to the recipient heart. Pilot trials have shown the ability of the P-MEA to survive
implantation in vivo for the duration of the three week experiment, though additional
experiments are required to fully assses P-MEA biocompatibility and functional
coupling. These data will be valuable in guiding the pre-clinical translation of this
approach.
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6.3 Pending Outcomes
1. The following manuscript is in revision after a favorable review:
Trada H, Vendra V, Tinney JP, Yuan, FP, Jackson D, Walsh K, Keller BB.
Implantable thin-film porous microelectrode array sensor (P-MEA-S) for electrical
stimulation of engineered cardiac tissues. BioChip Journal (in revision, Dec. 2014).
2. Ongoing experiments are utilizing the P-MEA to evaluate the effect of chronic
electrical stimulation on the structural and functional maturation of ECTs generated
from human-iPS derived CM and murine-ASC derived CM. These studies will lead to
additional publications where I will be a contributing author.
3. A provisional patent has been filed by UofL related to the reduction to practice of
the P-MEA device.
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APPENDIIX

Mask
k 1 of P-MEA
A (version 33), (layout inn L-Edit).
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Mask
k 2 of P-MEA
A (version 33), (layout inn L-Edit).
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